SAS Analysis finds that the difficulty of scaling clinical AI pilots usually stems not from the algorithms, but from whether the data, validation, documentation, and governance environment can meet traceability and reproducibility requirements. SAS and IDC’s 2026 Data and AI Impact Report shows that only 17.5% of organizations have the highest level of data infrastructure maturity. Among the cohort with the strongest trustworthy AI practices, 55% expect strong or high ROI, compared with just 11% in the weakest cohort.
Source:Biotech and Pharma Industry News · Read Original
Leave a Reply